Project No.: TAČR TO01000107 Project Partner’s #1 Agreement No.: -

Project Promoter’s Agreement No.: REG-38-2024 Project Partner’s #2 Agreement No.: -

Project Partner’s #3 Agreement No.: -

**Agreement**

on Utilisation of Results

“Development of standardized culture, transplantation and banking of RPE cells  
for treatment of agerelated macular degeneration (AMD)”

On the day, month and year indicated below, the Agreement Parties concluded

**Institute of Animal Physiology and Genetics CAS, v. v. i.**

headquarters: Rumburská 89, Liběchov, Postal code 277 21

ID no.: 67985904 (Czech Republic)

represented by: Ing. Michal Kubelka, CSc., director

hereinafter referred to as the “**Project Promoter**”

on the first side

and

**Institute of Macromolecular Chemistry CAS, v. v. i.**

headquarters: Heyrovského náměstí 1888/2, Praha 6 – Břevnov, Postal code 162 00

ID no.: 61389013 (Czech Republic)

represented by: Dr. Ing. Jiří Kotek, dr.h.c., director

hereinafter referred to as the “**Project Partner #1**”

on the second side

and

**University of Oslo**

headquarters: Problemveien 7, Oslo, Postal code 0313

ID no.: 971035854 (Kingdom of Norway)

represented by: Astrid Aksnessæther, head of administration at the Institute for Clinical Medicine

hereinafter referred to as the “**Project Partner #2**”

on the third side

and

**University Hospital Královské Vinohrady**

headquarters: Šrobárova 1150/50, Praha 10 – Vinohrady, Postal code 101 00

ID no.: 00064173 (Czech Republic)

represented by: MUDr. Jan Votava, MBA, director

hereinafter referred to as the “**Project Partner #3**”

on the fourth side

this

**Agreement on Utilisation of Results**

**“Development of standardized culture, transplantation and banking of RPE cells  
for treatment of agerelated macular degeneration (AMD)”**

hereinafter referred to as the “**Agreement**”

1. Introductory Provisions
   1. The purpose of this Agreement is to regulate the mutual rights and obligations of the Agreement Parties to the results of applied research carried out by the Agreement Parties and financed by special-purpose support pursuant to Czech Act No. 130/2002 Coll., on Support for Research, Experimental Development and Innovation from Public Funds and on Amendments to Certain Related Acts, as amended (hereinafter referred to as the “**Research Support Act**”), and their use by the Agreement Parties.
   2. The scope and content of the mutual rights and obligations of the Agreement Parties shall be governed by the Agreement, the Research Support Act, Czech Act No. 121/2000 Coll., on Copyright, on Rights Related to Copyright and on Amendments to Certain Acts, as amended (hereinafter referred to as the “**Copyright Act**”), and the relevant provisions of Czech Act No. 89/2012 Coll., Civil Code, as amended (hereinafter referred to as the “**Civil Code**”), and the Agreement is concluded pursuant to the provisions of Section 1746(2) of the Civil Code as an innominate contract based primarily on co-ownership (Section 1115 et seq.) and licence (Section 2358 et seq.).
   3. The creation of the results of applied research was financed under the KAPPA Programme for Industrial Research, Experimental Development and Innovation (the Programme) financed under the legal framework of EEA and Norway Grants 2014 – 2021 (the EEA and Norway Grants), for which the provider was Czech Republic – Technology Agency of the Czech Republic with registered office at Evropská 1692/37, Praha 6 – Dejvice, Postal Code 160 00, ID No. TO01000107 entitled “*Standardised culture, transplantation and storage of RPE cells for the treatment of age-related macular degeneration (AMD)*” (hereinafter referred to as the “**Project**”).
2. Project Results, ownership and use
   1. The Agreement Parties **define the results** of the applied research in the Project (hereinafter referred to as the “**Project Results**”) **and compare them with the objectives** of the Project as follows:
      1. **Subretinal implantation of cultured retinal pigment epithelium on a degradable nanofibrous carrier: procedures for preoperative preparation, surgical techniques, and postoperative care** (code TO01000107-V1)

▪ type: Ztech – Verified technology

*This is the surgical methodology of subretinal implantation of cultured retinal pigment epithelium on a degradable nanofibrous carrier: preoperative preparation procedures, surgical techniques and postoperative care.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objectives of the Project in relation to the Project Result:

3. transplantation of RPE cell-covered carriers into the subretinal space;

4. non-invasive (OCT, mfERG) and invasive (IHC and TEM) post-operative monitoring.

status: objective(s) achieved

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V2)

▪ type: Jimp – Peer-reviewed scientific article

*This is a peer-reviewed article “Subretinal implantation of human primary RPE cells cultured on nanofibrous membranes in minipigs” published in the impacted journal Biomedicines.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objectives of the Project in relation to the Project Result:

3. transplantation of RPE cell-coated carriers into the subretinal space;

4. non-invasive (OCT, mfERG) and invasive (IHC and TEM) post-operative monitoring.

status: objective(s) achieved

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V3)

▪ type: Jimp – Peer-reviewed scientific article

*This is a peer-reviewed article “Advances in nanostructure-based tissue biomaterials for retinal degenerative diseases” published in the impacted journal Biomedicines.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objective of the Project in relation to the Project Result:

2. preparation of nanofibrous carriers.

status: objective(s) achieved

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V4)

▪ type: Jost – Peer-reviewed scientific article

*This is a peer-reviewed article “Mitochondrial dysfunction in a minipig retinal ischemia model induced by high intraocular pressure” published in the impacted journal Biomolecules.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

status: objective(s) achieved

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V5)

▪ type: Jimp – Peer-reviewed scientific article

*This is the peer-reviewed article “Subretinal implantation of RPE on a carrier in minipigs: Guidelines for preoperative preparation, surgical techniques and postoperative care” published in the impacted journal JoVE.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objectives of the Project in relation to the Project Result:

1. isolation and culture of human RPE cells (hRPE), both primary hRPE cells and hRPE cells derived from human induced pluripotent cells (hiPS);

2. preparation of nanofibrous carriers;

3. transplantation of RPE cell-coated carriers into the subretinal space;

4. non-invasive (OCT, mfERG) and invasive (IHC and TEM) post-operative monitoring.

status: objective(s) achieved

* + 1. **Validated technology “Biodegradable polylactide-based nanofibrous membranes with incorporated support frame for retinal pigment epithelium culture”** (code TO01000107-V6)

▪ type: Ztech – Verified technology

*This is a validated technology “Biodegradable polylactide-based nanofibrous membranes with incorporated support frame for retinal pigment epithelium culture”.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objective of the Project in relation to the Project Result:

2. preparation of nanofibre carriers.

status: objective(s) achieved

* + 1. **Chapter in a specialist book** (code TO01000107-V7)

▪ type: C – Chapter in a specialist book

*This is the chapter “Retinal pigment epithelium: at the forefront of the hematoretinal barrier in physiology and disease” in the reference book Tissue Barriers in Disease, Injury and Regeneration (978-0-12-818561-2).*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objective of the Project in relation to the Project Result:

5. establishing Good Laboratory Practice (GLP) protocols for cell isolation, long-term storage and transplantation.

status: objective(s) achieved

* + 1. **Scientific article** (code TO01000107-V8)

▪ type: O – Miscellaneous

*This is the article “Advantages of nanofibrous membranes for culturing primary RPE cells compared to commercial carriers” published in Acta Ophthalmologica.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

Sub-objective of the Project in relation to the Project Result:

2. preparation of nanofibre carriers.

status: objective(s) achieved

* + 1. **Workshop** (code TO01000107-V9)

▪ type: O – Miscellaneous

*It is a workshop “Gene and cell therapy of neurodegenerative and eye diseases” with the participation of all teams involved in the Project.*

▪ status: result achieved and used

▪ Project/output/outcome objective(s):

The objective of the Project is to develop a standardized, safe and effective method for the treatment of the dry form of age-related macular degeneration (AMD), for which there is no effective treatment yet.

The Project aims to bring cell therapy for AMD based on retinal pigment epithelial (RPE) cell transplantation into clinical trials.

The aim was to internationalize – to involve international cell therapy teams in the Project.

status: objective(s) achieved

* 1. The Agreement Parties define the **ownership rights to the Project Results** as follows:
     1. **Subretinal implantation of cultured retinal pigment epithelium on a degradable nanofibrous carrier: procedures for preoperative preparation, surgical techniques, and postoperative care** (code TO01000107-V1)

▪ ownership share of the Project Promoter: 30 %

▪ ownership share of the Project Partner #1: 0 %

▪ ownership share of the Project Partner #2: 0 %

▪ ownership share of the Project Partner #3: 70 %

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V2)

▪ ownership share of the Project Promoter: 20 %

▪ ownership share of the Project Partner #1: 20 %

▪ ownership share of the Project Partner #2: 40 %

▪ ownership share of the Project Partner #3: 20 %

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V3)

▪ ownership share of the Project Promoter: 100 %

▪ ownership share of the Project Partner #1: 0 %

▪ ownership share of the Project Partner #2: 0 %

▪ ownership share of the Project Partner #3: 0 %

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V4)

▪ ownership share of the Project Promoter: 50 %

▪ ownership share of the Project Partner #1: 0 %

▪ ownership share of the Project Partner #2: 50 %

▪ ownership share of the Project Partner #3: 0 %

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V5)

▪ ownership share of the Project Promoter: 40 %

▪ ownership share of the Project Partner #1: 20 %

▪ ownership share of the Project Partner #2: 20 %

▪ ownership share of the Project Partner #3: 20 %

* + 1. **Validated technology “Biodegradable polylactide-based nanofibrous membranes with incorporated support frame for retinal pigment epithelium culture”** (code TO01000107-V6)

▪ ownership share of the Project Promoter: 0 %

▪ ownership share of the Project Partner #1: 100 %

▪ ownership share of the Project Partner #2: 0 %

▪ ownership share of the Project Partner #3: 0 %

* + 1. **Chapter in a specialist book** (code TO01000107-V7)

▪ ownership share of the Project Promoter: 50 %

▪ ownership share of the Project Partner #1: 0 %

▪ ownership share of the Project Partner #2: 50 %

▪ ownership share of the Project Partner #3: 0 %

* + 1. **Scientific article** (code TO01000107-V8)

▪ ownership share of the Project Promoter: 40 %

▪ ownership share of the Project Partner #1: 20 %

▪ ownership share of the Project Partner #2: 20 %

▪ ownership share of the Project Partner #3: 20 %

* + 1. **Workshop** (code TO01000107-V9)

▪ ownership share of the Project Promoter: 100 %

▪ ownership share of the Project Partner #1: 0 %

▪ ownership share of the Project Partner #2: 0 %

▪ ownership share of the Project Partner #3: 0 %

* 1. The Project Promoter hereby grants, *to the extent vested in it*, to Project Partner #1, Project Partner #2 and Project Partner #3 the right to use the Project Results to the extent specified below, and Project Partner #1, Project Partner #2 and Project Partner #3 hereby accept this right and undertake to use it to the extent agreed,

similarly, Project Partner #1 hereby grants, *to the extent vested in it*, to the Project Promoter, Project Partner #2 and Project Partner #3, to the extent hereinafter provided, the right to use the Project Results, and the Recipient, Project Partner #2 and Project Partner #3 hereby accept and undertake to use such right to the extent agreed; and

similarly, Project Partner #2 hereby grants, *to the extent vested in it*, to the Project Promoter, Project Partner #1 and Project Partner #3, to the extent hereinafter provided, the right to use the Project Results, and the Recipient, Project Partner #1 and Project Partner #3 hereby accept and undertake to use such right to the extent agreed; and

similarly, Project Partner #3 hereby grants, *to the extent vested in it*, to the Project Promoter, Project Partner #1 and Project Partner #2, to the extent hereinafter provided, the right to use the Project Results and the Recipient, Project Partner #1 and Project Partner #2 hereby accept and undertake to use such right to the extent agreed.

* + 1. **Subretinal implantation of cultured retinal pigment epithelium on a degradable nanofibrous carrier: procedures for preoperative preparation, surgical techniques, and postoperative care** (code TO01000107-V1)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by all interested parties on a non-exclusive and non-discriminatory basis as from 03/2024 and for at least 5 years after the end of the Project.

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V2)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 03/2022 and for at least 5 years after the end of the Project.

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V3)

▪ Project Promoter is entitled to use the result independently.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 08/2021 and for at least 5 years after the end of the Project.

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V4)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 10/2022 and for at least 5 years after the end of the Project.

* + 1. **Peer reviewed article in an international journal** (code TO01000107-V5)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 03/2024 and for at least 5 years after the end of the Project.

* + 1. **Validated technology “Biodegradable polylactide-based nanofibrous membranes with incorporated support frame for retinal pigment epithelium culture”** (code TO01000107-V6)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by all interested parties on a non-exclusive and non-discriminatory basis as from 03/2024 and for at least 5 years after the end of the Project.

* + 1. **Chapter in a specialist book** (code TO01000107-V7)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 06/2021 and for at least 5 years after the end of the Project.

* + 1. **Scientific article** (code TO01000107-V8)

▪ Project Promoter is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 11/2021 and for at least 5 years after the end of the Project.

* + 1. **Workshop** (code TO01000107-V9)

▪ Project Promoter is entitled to use the result independently.

▪ Project Partner #1 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #2 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

▪ Project Partner #3 is entitled to use the result independently for any non-commercial purposes, in particular for research, development and educational purposes.

Project Result is made available for use by the professional and wider public (including use in further research and practice) from 11/2023 and for at least 5 years after the end of the Project.

* 1. It is said that
     1. the granting of a right of use (license or sub-license) of the Project Result to a third party is subject to the prior written consent of all its co-owners; and
     2. commercial exploitation of the Project Result is subject to the prior written consent of all its co-owners and compensation corresponding at least to the market price and the share of ownership of each co-owner in the Project Result.
  2. Project Partner #1, Project Partner #2 and Project Partner #3 are each separately obliged to provide the Project Promoter with information on the use of the Project Results for the previous calendar year no later than 30th June 2026, 30th June 2027 and 30th June 2028 for the purpose of preparing the respective report on the implementation of the Project Results by the Project Promoter to the Programme Operator.
  3. The right to use the Project Results is granted free of charge, in the territory of the Czech Republic (Project Promoter, Project Partner #1 and Project Partner #3) and the Kingdom of Norway (Project Partner #2) and for the duration of the property rights as non-exclusive.
  4. When the Project Results are published in printed form in the form of scientific or technical publications or presentations, it must also be stated that the Project Results have been achieved in collaboration with other participants.
  5. The Project Results are not subject to protection under special legal regulations as to their confidentiality – they are not classified information.
  6. The Agreement Parties have entrusted the following persons with the performance of the subject matter of the Agreement
     1. on behalf of Project Promoter

xxx

* + 1. on behalf of Project Partner #1

xxx

* + 1. on behalf of Project Partner #2

xxx

* + 1. on behalf of Project Partner #3

xxx

In the absence of an amendment to the Agreement, the persons named herein shall act in the performance of this Agreement. Prior written notice to the other Agreement Parties shall be sufficient to change the persons responsible for the performance of the subject matter of the Agreement.

1. Contractual sanctions
   1. If a contractual penalty or default interest is agreed upon under the Agreement or provided for by law, its application is at the will of the entitled Agreement Party.
   2. The application of a contractual penalty or default interest shall be without prejudice to the rights of liability for damages.
   3. The Agreement Parties agree
      1. a contractual penalty in the amount of CZK 500.00 for each day of delay in providing information on the use of the Project Results for the purpose of preparing the relevant report on the implementation of the Project Results by the Project Promoter to the Programme Operator;
      2. a contractual penalty of CZK 50,000.00 for each individual case of exceeding the agreed purpose of use of the Project Results; and
      3. a contractual penalty of CZK 100,000.00 for each individual case of infringement of intellectual property rights in the Project Results.
2. Other and final Agreement provisions
   1. The Agreement Parties undertake to resolve any disputes arising from this Agreement in an amicable manner.
   2. The invalidity of any provision of this Agreement shall not invalidate the entire Agreement.
   3. The Agreement may be amended by the Agreement Parties only by written amendments, which shall be numbered in ascending order, expressly declared to be an amendment to this Agreement and signed by authorized representatives of the Agreement Parties, unless this Agreement expressly provides that no amendment need be entered into.
   4. Either Agreement Party may terminate this Agreement in writing, even without giving any reason. The period of notice shall be 3 calendar months and shall be effective only against the Agreement Party that has terminated the Agreement.
   5. In the event of termination of the Agreement prior to its full performance, the provisions of the Agreement which are in the legitimate interest of the Agreement Parties (in particular the interest in the use of the results, compensation for damages) shall remain in force and effect regardless of the method of termination. The same shall apply in the event of termination of the Agreement Contract in relation to one of the Agreement Parties only - the provisions of the Agreement in respect of such (former) Agreement Party shall remain in force and effect if the other Agreement Parties have a legitimate interest in maintaining them.
   6. The Agreement Parties have disclosed to each other all facts and legal circumstances of which they knew or ought to have known at the date of conclusion of the Agreement and which are relevant in relation to the conclusion of the Agreement. Apart from the representations made by the Agreement Parties to each other in the Agreement, neither Agreement Party shall have any further rights or obligations in respect of any facts which come to light which were not disclosed by that Agreement Party in the negotiation of the Agreement. The exception to this will be where an Agreement Party has deliberately misled the other Agreement Parties as to the subject matter of the Agreement.
   7. The Agreement Parties declare that they have read the Agreement before signing it and that it has been concluded after mutual negotiation according to their true and free will in a certain, serious and comprehensible manner, not under duress or under manifestly unfavourable conditions, and that they have agreed on its entire content, which they confirm by their signatures.
   8. Within the meaning of Act No. 106/1999 Coll., on free access to information, as amended, the Agreement Parties acknowledge that they are obliged entities within the meaning of this Act and for this purpose they mutually agree to provide all information contained in this Agreement to the applicants.
   9. The Agreement comes into validity on the date of affixing the signatures of all Agreement Parties, or of their representatives, to this Agreement, on the date of the last of them joining.
   10. The Agreement becomes effective on the date of its publication in the Register of Contracts pursuant to Act No. 340/2015 Coll., on special conditions for the effectiveness of certain contracts, publication of these contracts and on the register of contracts (Act on the Register of Contracts), as amended. Publication will be made by the Recipient.
   11. As proof of their agreement with the content of the Agreement, the Contracting Parties have attached the signatures of their authorized representatives to it and have determined that they concluded the Agreement in this way.

In Liběchov 2. 8. 2024 In Prague 25. 6. 2024

on behalf of the Project Promoter: on behalf of the Project Partner #1:

Ing. Michal Kubelka, CSc. Dr. Ing. Jiří Kotek, dr.h.c.

director of the Institute director of the Institute

of Animal Physiology and Genetics CAS, v. v. i. of Macromolecular Chemistry CAS, v. v. i.

In Oslo 20. 6. 2024 In Prague 10. 7. 2024

on behalf of the Project Partner #2: on behalf of the Project Partner #3:

Astrid Aksnessæther MUDr. Jan Votava, MBA

head of administration at the Institute director of the

for Clinical Medicine at The University of Oslo University Hospital Královské Vinohrady